K. Yoshino, M. Tamba, H. Osumi, S. Fukuoka, M. Ogura, S. Udagawa, K. Shimozaki, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, K. Chin, A. Ooki
{"title":"免疫检查点抑制剂治疗转移性食管鳞状细胞癌的预后营养指标","authors":"K. Yoshino, M. Tamba, H. Osumi, S. Fukuoka, M. Ogura, S. Udagawa, K. Shimozaki, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, K. Chin, A. Ooki","doi":"10.1016/j.esmogo.2025.100222","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The prognostic nutritional index (PNI) is an inflammation- and nutrition-based indicator that serves as a prognostic factor for various cancer types. This study aimed to evaluate the association between PNI and survival in patients with esophageal squamous-cell carcinoma (ESCC) receiving immune checkpoint inhibitor (ICI)-based therapies.</div></div><div><h3>Materials and methods</h3><div>This single-center retrospective study included two cohorts: 109 patients treated with nivolumab monotherapy as second-line or later therapy and 92 patients receiving first-line ICI-based treatments (ICI plus chemotherapy or nivolumab plus ipilimumab).</div></div><div><h3>Results</h3><div>In the nivolumab monotherapy cohort, higher PNI (PNI ≥ 40.5) was linked to longer overall survival (OS) compared with lower PNI (16.2 versus 5.5 months, <em>P</em> = 0.001). In the first-line cohort, 92 patients received ICI plus chemotherapy (<em>n</em> = 60) or nivolumab plus ipilimumab (<em>n</em> = 32). Higher PNI was linked to better OS in both the ICI plus chemotherapy (21.2 versus 7.7 months, <em>P</em> = 0.0008) and the nivolumab plus ipilimumab (not reached versus 10.2 months, <em>P</em> = 0.02) cohorts. Multivariate analysis identified PNI status as an independent prognostic factor in both cohorts. Dynamic changes in PNI (delta PNI ≥ 1.25) 1 month after treatment were linked to better progression-free survival in patients with lower PNI receiving nivolumab monotherapy or nivolumab plus ipilimumab but not in those receiving first-line ICI plus chemotherapy.</div></div><div><h3>Conclusions</h3><div>PNI and its dynamic changes may serve as useful indicators of prognosis in patients with ESCC receiving ICI-based therapies.</div></div>","PeriodicalId":100490,"journal":{"name":"ESMO Gastrointestinal Oncology","volume":"9 ","pages":"Article 100222"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor\",\"authors\":\"K. Yoshino, M. Tamba, H. Osumi, S. Fukuoka, M. Ogura, S. Udagawa, K. Shimozaki, T. Wakatsuki, E. Shinozaki, K. Yamaguchi, K. Chin, A. Ooki\",\"doi\":\"10.1016/j.esmogo.2025.100222\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The prognostic nutritional index (PNI) is an inflammation- and nutrition-based indicator that serves as a prognostic factor for various cancer types. This study aimed to evaluate the association between PNI and survival in patients with esophageal squamous-cell carcinoma (ESCC) receiving immune checkpoint inhibitor (ICI)-based therapies.</div></div><div><h3>Materials and methods</h3><div>This single-center retrospective study included two cohorts: 109 patients treated with nivolumab monotherapy as second-line or later therapy and 92 patients receiving first-line ICI-based treatments (ICI plus chemotherapy or nivolumab plus ipilimumab).</div></div><div><h3>Results</h3><div>In the nivolumab monotherapy cohort, higher PNI (PNI ≥ 40.5) was linked to longer overall survival (OS) compared with lower PNI (16.2 versus 5.5 months, <em>P</em> = 0.001). In the first-line cohort, 92 patients received ICI plus chemotherapy (<em>n</em> = 60) or nivolumab plus ipilimumab (<em>n</em> = 32). Higher PNI was linked to better OS in both the ICI plus chemotherapy (21.2 versus 7.7 months, <em>P</em> = 0.0008) and the nivolumab plus ipilimumab (not reached versus 10.2 months, <em>P</em> = 0.02) cohorts. Multivariate analysis identified PNI status as an independent prognostic factor in both cohorts. Dynamic changes in PNI (delta PNI ≥ 1.25) 1 month after treatment were linked to better progression-free survival in patients with lower PNI receiving nivolumab monotherapy or nivolumab plus ipilimumab but not in those receiving first-line ICI plus chemotherapy.</div></div><div><h3>Conclusions</h3><div>PNI and its dynamic changes may serve as useful indicators of prognosis in patients with ESCC receiving ICI-based therapies.</div></div>\",\"PeriodicalId\":100490,\"journal\":{\"name\":\"ESMO Gastrointestinal Oncology\",\"volume\":\"9 \",\"pages\":\"Article 100222\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESMO Gastrointestinal Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949819825000913\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESMO Gastrointestinal Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949819825000913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Prognostic nutritional index as a prognostic marker in metastatic esophageal squamous-cell carcinoma treated with immune checkpoint inhibitor
Background
The prognostic nutritional index (PNI) is an inflammation- and nutrition-based indicator that serves as a prognostic factor for various cancer types. This study aimed to evaluate the association between PNI and survival in patients with esophageal squamous-cell carcinoma (ESCC) receiving immune checkpoint inhibitor (ICI)-based therapies.
Materials and methods
This single-center retrospective study included two cohorts: 109 patients treated with nivolumab monotherapy as second-line or later therapy and 92 patients receiving first-line ICI-based treatments (ICI plus chemotherapy or nivolumab plus ipilimumab).
Results
In the nivolumab monotherapy cohort, higher PNI (PNI ≥ 40.5) was linked to longer overall survival (OS) compared with lower PNI (16.2 versus 5.5 months, P = 0.001). In the first-line cohort, 92 patients received ICI plus chemotherapy (n = 60) or nivolumab plus ipilimumab (n = 32). Higher PNI was linked to better OS in both the ICI plus chemotherapy (21.2 versus 7.7 months, P = 0.0008) and the nivolumab plus ipilimumab (not reached versus 10.2 months, P = 0.02) cohorts. Multivariate analysis identified PNI status as an independent prognostic factor in both cohorts. Dynamic changes in PNI (delta PNI ≥ 1.25) 1 month after treatment were linked to better progression-free survival in patients with lower PNI receiving nivolumab monotherapy or nivolumab plus ipilimumab but not in those receiving first-line ICI plus chemotherapy.
Conclusions
PNI and its dynamic changes may serve as useful indicators of prognosis in patients with ESCC receiving ICI-based therapies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
